Literature DB >> 18838479

Autoimmune conditions and chronic infections in chronic lymphocytic leukemia patients at diagnosis are associated with unmutated IgVH genes.

Katrina Vanura1, Trang Le, Harald Esterbauer, Florentin Späth, Edit Porpaczy, Medhat Shehata, Karin Eigenberger, Alexander Hauswirth, Cathrin Skrabs, Elisabeth Krömer, Ilse Schwarzinger, Berthold Streubel, Christoph Steininger, Christa Fonatsch, Stephan Stilgenbauer, Oswald Wagner, Alexander Gaiger, Ulrich Jäger.   

Abstract

Few data are available concerning the prevalence of autoimmune disease or chronic infections in chronic lymphocytic leukemia patients at diagnosis as well as their clinical outcome. We studied the frequency of such chronic conditions in relation to prognostic markers. A history of autoimmune disease or chronic infection was found in 21% of 186 chronic lymphocytic leukemia patients (12% in autoimmune diseases, 9% in chronic infections). Patients with a history of chronic stimulation were more likely to have unmutated IgV(H) genes (p<0.002), unfavorable or intermediate risk cytogenetics (11q, 17p deletions, trisomy 12) (p<0.001), and higher CD38 expression (p=0.004). Autoimmune conditions (n=22) were characterized by female predominance (55.0%) with a high frequency of unmutated IgV(H) (53,8%). Median time to first treatment was 83 months for the chronic stimulation group compared to 128 months for the non-chronic stimulation group (n.s.). Patients suffering from chronic conditions at chronic lymphocytic leukemia diagnosis are likely to have poor prognostic markers, particularly unmutated IgV(H) genes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18838479     DOI: 10.3324/haematol.12955

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  8 in total

1.  Clinical and serological autoimmune complications in chronic lymphocytic leukemia.

Authors:  Cengiz Demir; Ömer Ekinci
Journal:  Wien Klin Wochenschr       Date:  2017-05-05       Impact factor: 1.704

2.  Recombinant antibodies encoded by IGHV1-69 react with pUL32, a phosphoprotein of cytomegalovirus and B-cell superantigen.

Authors:  Christoph Steininger; George F Widhopf; Emanuela M Ghia; Christopher S Morello; Katrina Vanura; Rebecca Sanders; Deborah Spector; Don Guiney; Ulrich Jäger; Thomas J Kipps
Journal:  Blood       Date:  2012-01-10       Impact factor: 22.113

Review 3.  Chronic lymphocytic leukemia and autoimmunity: a systematic review.

Authors:  Kate Hodgson; Gerardo Ferrer; Emili Montserrat; Carol Moreno
Journal:  Haematologica       Date:  2011-01-17       Impact factor: 9.941

4.  Relative seroprevalence of human herpes viruses in patients with chronic lymphocytic leukaemia.

Authors:  C Steininger; L Z Rassenti; K Vanura; K Eigenberger; U Jäger; T J Kipps; C Mannhalter; S Stilgenbauer; T Popow-Kraupp
Journal:  Eur J Clin Invest       Date:  2009-06       Impact factor: 4.686

5.  Pathological RANK signaling in B cells drives autoimmunity and chronic lymphocytic leukemia.

Authors:  Begüm Alankus; Veronika Ecker; Nathalie Vahl; Martina Braun; Wilko Weichert; Stephan Macher-Göppinger; Torben Gehring; Tanja Neumayer; Thorsten Zenz; Maike Buchner; Jürgen Ruland
Journal:  J Exp Med       Date:  2021-02-01       Impact factor: 14.307

6.  The use of monoclonal antibodies in the treatment of autoimmune complications of chronic lymphocytic leukemia.

Authors:  Luca Laurenti; Barbara Vannata; Idanna Innocenti; Francesco Autore; Francesco Santini; Simona Sica; Dimitar G Efremov
Journal:  Mediterr J Hematol Infect Dis       Date:  2013-04-10       Impact factor: 2.576

7.  Associations of environment, health history, T-zone lymphoma, and T-zone-like cells of undetermined significance: A case-control study of aged Golden Retrievers.

Authors:  Julia D Labadie; Sheryl Magzamen; Paul S Morley; G Brooke Anderson; Janna Yoshimoto; Anne C Avery
Journal:  J Vet Intern Med       Date:  2019-01-21       Impact factor: 3.333

Review 8.  Can Immunocompetence Be Restored in Chronic Lymphocytic Leukemia?

Authors:  Clare Sun; Adrian Wiestner
Journal:  Hematol Oncol Clin North Am       Date:  2021-05-26       Impact factor: 2.861

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.